Market News AIOpen the app

Eikon Therapeutics, Inc. shares new clinical data from its research at a big medical conference.

TrialRead the original at SEC EDGAR
Neutral

Eikon’s EIK1003 studies found tumor responses, but response rates varied and severe side effects affected 43% of patients in the single-drug group. Combination results remain early, so the findings do not yet change the company’s outlook.

EIKN · Eikon Therapeutics, Inc.

AI read · Neutral

The AI's read

Response rates differed by prior treatment: 31% among people who had not previously taken a PARP cancer drug, versus 6% among those who had. Severe side effects affected 43% of the single-drug group and 45% of the abiraterone group. The combination studies showed early signs of activity, but the varied results and side effects leave Eikon’s outlook unchanged for now.

Get alerts for EIKN

Follow Eikon Therapeutics, Inc. (EIKN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EIKN
Free on the App Store and Google Play, or on the web.